Taylor & Francis
Expert Review of Anticancer Therapy
,  volume 22 ,  issue 1 ,  pages 115-121

Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21)

Alessia Mennitto 1
, 
Emma Zattarin 1
, 
Massimo Di Maio 2
, 
Davide Bimbatti 3
, 
Ugo De Giorgi 4
, 
Sebastiano Buti 5
, 
Daniele Santini 6
, 
Chiara Casadei 4
, 
Mariella Soraru’ 7
, 
Carlo Messina 8
, 
Claudia Mucciarini 9
, 
Giuseppe Di-Lorenzo 10, 11
, 
Giandomenico Roviello 12
, 
Consuelo Buttigliero 13
, 
Marco Stellato 6
, 
Pierangela Sepe 1
, 
Melanie Claps 1
, 
Valentina Guadalupi 1
, 
Arianna Ottini 1
, 
Sandro Pignata 14
, 
Filippo de Braud 1, 15
, 
Filippo G De Braud 1, 15
, 
Elena Verzoni 1
, 
Giuseppe Procopio 1
1
 
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy | 
2
 
3
 
4
 
5
 
Medical Oncology Unit, University Hospital of Parma, Parma, Italy | 
6
 
7
 
Medical Oncology, Camposampiero Hospital, Camposampiero (Padua), Italy | 
8
 
Department of Medical Oncology, Santa Chiara Hospital, Trento, Italy | 
9
 
Medical Oncology Unit, Ramazzini Hospital, Carpi, Italy | 
10
 
Oncology Unit, Andrea Tortora Hospital, ASL Salerno, Pagani, Italy | 
11
 
12
 
13
 
Medical Oncology, San Luigi Gonzaga Hospital, Orbassano, Italy | 
14
 
15
 
Publication type: Journal Article
Publication date: 2021-11-29
Taylor & Francis
scimago Q2
wos Q2
SJR: 0.926
CiteScore: 5.2
Impact factor: 2.8
ISSN: 14737140, 17448328
Oncology
Pharmacology (medical)
Found 
Found 

Top-30

Journals

1
Tumori
Tumori, 1, 16.67%
Tumori
1 publication, 16.67%
Expert Review of Precision Medicine and Drug Development
Expert Review of Precision Medicine and Drug Development, 1, 16.67%
Expert Review of Precision Medicine and Drug Development
1 publication, 16.67%
Clinical Genitourinary Cancer
Clinical Genitourinary Cancer, 1, 16.67%
Clinical Genitourinary Cancer
1 publication, 16.67%
Medicina
Medicina, 1, 16.67%
Medicina
1 publication, 16.67%
Genes
Genes, 1, 16.67%
Genes
1 publication, 16.67%
European Urology Open Science
European Urology Open Science, 1, 16.67%
European Urology Open Science
1 publication, 16.67%
1

Publishers

1
2
Elsevier
Elsevier, 2, 33.33%
Elsevier
2 publications, 33.33%
MDPI
MDPI, 2, 33.33%
MDPI
2 publications, 33.33%
SAGE
SAGE, 1, 16.67%
SAGE
1 publication, 16.67%
Taylor & Francis
Taylor & Francis, 1, 16.67%
Taylor & Francis
1 publication, 16.67%
1
2
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
6
Share
Cite this
GOST |
Cite this
GOST Copy
Mennitto A. et al. Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21) // Expert Review of Anticancer Therapy. 2021. Vol. 22. No. 1. pp. 115-121.
GOST all authors (up to 50) Copy
Mennitto A., Zattarin E., Di Maio M., Bimbatti D., De Giorgi U., Buti S., Santini D., Casadei C., Soraru’ M., Messina C., Mucciarini C., Di-Lorenzo G., Roviello G., Buttigliero C., Stellato M., Sepe P., Claps M., Guadalupi V., Ottini A., Pignata S., Braud F. D., De Braud F. G., Verzoni E., Procopio G. Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21) // Expert Review of Anticancer Therapy. 2021. Vol. 22. No. 1. pp. 115-121.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1080/14737140.2022.2002688
UR - https://doi.org/10.1080/14737140.2022.2002688
TI - Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21)
T2 - Expert Review of Anticancer Therapy
AU - Mennitto, Alessia
AU - Zattarin, Emma
AU - Di Maio, Massimo
AU - Bimbatti, Davide
AU - De Giorgi, Ugo
AU - Buti, Sebastiano
AU - Santini, Daniele
AU - Casadei, Chiara
AU - Soraru’, Mariella
AU - Messina, Carlo
AU - Mucciarini, Claudia
AU - Di-Lorenzo, Giuseppe
AU - Roviello, Giandomenico
AU - Buttigliero, Consuelo
AU - Stellato, Marco
AU - Sepe, Pierangela
AU - Claps, Melanie
AU - Guadalupi, Valentina
AU - Ottini, Arianna
AU - Pignata, Sandro
AU - Braud, Filippo de
AU - De Braud, Filippo G
AU - Verzoni, Elena
AU - Procopio, Giuseppe
PY - 2021
DA - 2021/11/29
PB - Taylor & Francis
SP - 115-121
IS - 1
VL - 22
PMID - 34738499
SN - 1473-7140
SN - 1744-8328
ER -
BibTex |
Cite this
BibTex (up to 50 authors) Copy
@article{2021_Mennitto,
author = {Alessia Mennitto and Emma Zattarin and Massimo Di Maio and Davide Bimbatti and Ugo De Giorgi and Sebastiano Buti and Daniele Santini and Chiara Casadei and Mariella Soraru’ and Carlo Messina and Claudia Mucciarini and Giuseppe Di-Lorenzo and Giandomenico Roviello and Consuelo Buttigliero and Marco Stellato and Pierangela Sepe and Melanie Claps and Valentina Guadalupi and Arianna Ottini and Sandro Pignata and Filippo de Braud and Filippo G De Braud and Elena Verzoni and Giuseppe Procopio},
title = {Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21)},
journal = {Expert Review of Anticancer Therapy},
year = {2021},
volume = {22},
publisher = {Taylor & Francis},
month = {nov},
url = {https://doi.org/10.1080/14737140.2022.2002688},
number = {1},
pages = {115--121},
doi = {10.1080/14737140.2022.2002688}
}
MLA
Cite this
MLA Copy
Mennitto, Alessia, et al. “Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21).” Expert Review of Anticancer Therapy, vol. 22, no. 1, Nov. 2021, pp. 115-121. https://doi.org/10.1080/14737140.2022.2002688.